Professor Thomas Rademacher
Co-founder & CEO
Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation.
He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur. Professor Rademacher is considered one of the founders of biotech in the early 1980s (recombinant proteins, monoclonal antibodies, glycobiology) and as an academic scientist has over 200 publications and 50 patents in his name. He was co-Founder of the field of Glycobiology and subsequent Glycobiology Institute in Oxford. He co-founded Oxford GlycoSciences, the first of Oxford University’s biotech spinouts, which, in 1998, was listed on the London Stock Exchange and reached a market capitalisation of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd.
In 2000, he entered into a collaboration with the Spanish Research Council and co-founded the first nanomedicine company, Midatech Ltd. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015.
Professor Rademacher has authored over 200 publications and 50 patents – 19 of which are in the nanomedicine field. In addition to being a world leader in nanomedicine, he is also an expert in foetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia.